VivoSeq
Infectious Disease

Rotavirus Vaccine

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Rotavirus Vaccine is an early-stage landscape with 0 programs across 4 companies. The most active players are GSK, Shantha Biotechnics Limited, Bharat Biotech International Limited.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

98/100

Attrition Rate

2/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalS

Shantha Biotechnics Limited

0 programs

PreclinicalB

Bharat Biotech International Limited

0 programs

PreclinicalB

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

50

clinical trials

Completed42 · 84%
Active, not recruiting4 · 8%
Unknown status3 · 6%
Withdrawn1 · 2%

Clinical Trials

Trial Activity

50 trials

Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old
Active, not recruiting·BBeijing Zhifei Lvzhu Biopharmaceutical Co., Ltd·Phase 1·NCT06350058·375 enrolled
CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults
Active, not recruiting·Centers for Disease Control and Prevention·Phase 1·NCT06962904·50 enrolled
The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants
Active, not recruiting·BBharat Biotech International Limited·Phase 3·NCT06200844·5,800 enrolled
Optimising Rotavirus Vaccine in Aboriginal Children
Active, not recruiting·TTelethon Kids Institute·Phase 4·NCT02941107·1,000 enrolled
Response to Rotavirus Vaccine in Infants in Ho Chi Minh City in Vietnam
Completed·OOxford University Clinical Research Unit, Vietnam·Phase 4·NCT03587389·818 enrolled
Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants
Completed·GSK logoGSK·Phase 3·NCT02141204·451 enrolled
A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine).
Completed·GSK logoGSK·Phase 3·NCT00382772·1,200 enrolled
Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine
Completed·PPATH·Phase 2·NCT04344054·850 enrolled
An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)
Completed·—·Phase 4·NCT01960725·66 enrolled
Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa
Completed·CCentre for Infectious Disease Research in Zambia·Phase 2·NCT04658914·720 enrolled
A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine
Completed·MMurdoch Childrens Research Institute·Phase 2·NCT03483116·711 enrolled
Safety Study of a Rotavirus Vaccine (Rotavin-M1) Among Healthy Adults
Completed·National Institute of Hygiene and Epidemiology, Vietnam·Phase 1·NCT01375907·29 enrolled
Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months
Completed·GSK logoGSK·Phase 2·NCT00385320·2,640 enrolled
CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults
Completed·Centers for Disease Control and Prevention·Phase 1·NCT06485258·50 enrolled
To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants
Completed·GSK logoGSK·Phase 3·NCT00420745·1,009 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)